Physician profile
Anna Macgregor Bramwell
NPI 1922286111
$2,036.22
in general payments reported to CMS, 2019-2025
30 companies · $392 in 2025
The $392 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $74.53 · 2021: $441 · 2022: $340 · 2023: $352 · 2024: $240 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Long Term Medical Supply Or Device Loan: $28.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.75 |
| Long Term Medical Supply Or Device Loan | $28.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $312.85 | 2020-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $231.05 | 2023-2025 | |
| Corium, LLC | $200.69 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $165.67 | 2021-2025 | Qelbree |
| Kaleo, INC. | $115.43 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $101.42 | 2019-2024 | |
| Sanofi Pasteur INC. | $84.53 | 2022-2024 | |
| Seqirus USA INC | $74.50 | 2022-2025 | Flucelvax |
| Glaxosmithkline, LLC. | $72.25 | 2019-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $68.38 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.40 | 2021-2022 | |
| Abbvie INC. | $51.29 | 2021-2022 | |
| Tris Pharma INC | $49.16 | 2025 | Onyda Xr |
| Teva Pharmaceuticals USA, INC. | $48.53 | 2021-2022 | |
| Welch Allyn | $47.53 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $44.88 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $38.98 | 2019 | |
| Baxter Healthcare | $28.51 | 2025 | Hillrom - Spot Vision Screener |
| Biomarin Pharmaceutical INC. | $26.05 | 2024 | Voxzogo 1.2mg |
| Merck Sharp & Dohme LLC | $25.49 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $25.44 | 2023 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $24.68 | 2025 | Jornay Pm |
| Boston Scientific Corporation | $24.54 | 2023 | |
| Arbor Pharmaceuticals, INC. | $20.80 | 2019 | |
| Genentech USA, INC. | $17.29 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.65 | 2025 | Relexxii |
| Sobi, INC | $14.26 | 2022 | |
| Shire North American Group INC | $13.76 | 2019 | |
| Adlon Therapeutics L.P. | $13.34 | 2021 | |
| Phadia US INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bramwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.